The relationship between anticipated response and subsequent experience of cancer 1 treatment-related side effects: A meta-analysis comparing effects before and after treatment 2 exposure 3 4 Abstract 5
Introduction 1
Cancer patients report experiencing a range of treatment-related side effects including 2 pain, fatigue, nausea and vomiting, and even cognitive decline, although the nature and extent 3 of these can vary between individuals undergoing the same treatment 1 . Some side effects, 4 such as nausea, may be more common depending on the type of chemotherapy that theStudies were eligible for inclusion if they examined the relationship between patient 1 anticipation of side effects and their subsequent occurrence, duration, frequency, or severity 2 in patients undergoing cancer-related treatment. This included patients with no previous 3 treatment experience (potential "cognitive expectations" effect) or with some previous 4 treatment experience (potential "conditioned response"). The side effects included were 5 nausea, vomiting, fatigue, pain, skin reactions, and problems with concentration. 6 Eligible studies were required to meet the following criteria: 7 1) included participants undergoing curative treatment for cancer; 8
2) employed a measure of anticipated response to treatment; 9
3) examined the relationship between anticipation and experience of cancer treatment-10 related side effects; and 11 4) reported quantitative data (either an effect size or enough statistical information to 12 calculate an effect size). 13 Studies were excluded during the screening process if; anticipation of treatment-14 related side effects was not measured, the study was a review or meta-analysis of the 15 literature, the associations between anticipated and experienced side effects were not 16 reported, the sample was not cancer patients, the study focussed on mental health issues, or if 17 treatment was palliative or involved complementary and alternative therapies (i.e., not 18 adjuvant therapies used for curative purposes). 19 
2.3.Quality assessment 20
The first and third authors (CF and AH) assessed the methodological quality of 21 studies included in the meta-analysis using the Qualsyst tool 9 , which was developed for 22 assessment of the quality of both qualitative and quantitative studies that employ any study 23 design. The Qualsyst tool for assessment of the quality of quantitative studies is comprised of 1 14 items that are scored as yes, partial, no or not applicable. Examples of the items are; is the 2 question/objective sufficiently described, is the sample size appropriate, and have they 3 controlled for confounding. A summary score was calculated for each paper and then a final 4 score was calculated by dividing the summary score by the total possible score (determined 5
by subtracting the Not Applicable responses). Mean quality score for each paper was 6 calculated by averaging the scores given to each paper by the two assessors. These scores are 7 documented in Supplementary Table 1 (range: 0.66 to 1.0). The scores assigned by the first 8 assessor ranged from 0.59 to 1.0 (mean: 0.81, standard deviation: 0.09). The scores assigned 9
by the second assessor ranged from 0.64 to 1.0 (mean: 0.85, standard deviation: 0.10). Both 10 assessors assigned the same score to six studies (19%). Good inter-rater reliability was 11 observed (r = 0.60). Discrepancies in the scores of the remaining studies ranged from 0.01 to 12 0.18 and were resolved through discussion. Articles were not excluded from the meta-13 analysis based on a threshold Qualsyst score. 14
2.4.Data extraction 15
The first author (CF) extracted key descriptive data and effect sizes for the 16 relationship between anticipated response and subsequent experience of side effects. 17
Descriptive data extracted related to the study design (e.g., cross-sectional, 18 longitudinal/prospective, experimental), sample size, sample characteristics (e.g., gender, 19 cancer type, treatment type), whether participants had previous experience of cancer 20 treatment, instrument used to measure anticipation of treatment-related side effects, when 21 anticipation of side effects was measured (e.g., before first treatment, before treatment other 22 than the first, before multiple treatments), which side effects were experienced, and whether 23 occurrence, duration, frequency, or severity (or combination) of side effects were assessed.relationship between anticipated response and subsequent experience of side effects were also 1 extracted. 2
2.5.Data analysis 3

Effect size 4
The effect size correlation coefficient (ESr) was used as the outcome in the meta-5 analysis. Positive values indicated an association between anticipated response and 6 subsequent experience of the side effect measured by indices including, duration, frequency, 7 and severity. Effect sizes (Pearson's r) were directly available in many of the studies [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . In 8 cases where a correlation coefficient was not reported, mean side effects scores and standard 9 deviations 22 , t-tests 23 , number of side effect events and non-events 24 , chi-square statistics 25-10 27 , odds ratios [28] [29] [30] [31] , change in R square 23 , or Beta-coefficients 32-39 were used to estimate 11 effect sizes utilizing formulas suggested in the literature 40, 41 . 12 Several studies reported results for multiple indices of side effects (e.g., nausea 13 duration, nausea severity, and nausea unpleasantness) or multiple time-points (e.g., cycles of 14 chemotherapy). In these cases, an average effect size was calculated for each separate side 15 effect so that each study contributed only one effect size for each side effect to the meta-16 analysis. 17
Meta-analysis 18
The meta-analysis was conducted using Comprehensive Meta-Analysis Software V3 19 42 . Analyses were conducted separately for each side effect and for patients with and without 20 prior treatment experience. Overall effect sizes were calculated when relevant data were 21 available from at least three studies. Following recommendations by Borenstein and 22 colleagues 40 , a random-effects modelling approach was used to account for variation in 23 sampling in the included studies. Q tests were conducted to investigate differences in effect 1 sizes in patients with no prior treatment experience versus some prior treatment experience. 2
Heterogeneity 3
The I 2 statistic was calculated for each analysis to assess the consistency of the results 4 of included studies. The I 2 statistic describes the percentage of total variation between study 5 results that is due to genuine underlying differences (heterogeneity) rather than chance 43 . It is 6 a measure of inconsistency of results. According to Higgins and colleagues 43 , levels of 7 heterogeneity can be described as low (I 2 = 25%), moderate (I 2 = 50%), and high (I 2 = 75%), 8 with a lower level indicating less inconsistency in results. 9
Publication bias 10
Publication bias was assessed using Rosenthal's 44 Classic Fail-Safe N (N fs ), Orwin's 11 45 N fs , and Egger's test 46 . Rosenthal's N fs estimates the number of unpublished studies 12
reporting null results that would be needed to increase the P-value for the meta-analysis to 13 above 0.05. Orwin's N fs takes a more conservative approach to estimate the number of studies 14 needed to reduce the effect size to a specified level other than zero (defined in the present 15 meta-analysis as r ≤ 0.05). An effect size was considered to be robust if Rosenthal's N fs was 16 larger than 5k + 10, where k is the number of studies included in the analysis. Rosenthal's N fs 17 of less than the recommended criterion (5k + 10) indicated potential publication bias, which 18 was further investigated using Egger's test. Where Egger's test confirmed a publication bias, 19 an adjusted effect size was estimated using Duval and Tweedie's 47 trim-and-fill method, 20 which uses imputations of missing results to recalculate the effect size. 21
Results 22
3.1.Study Characteristics
12
The meta-analysis included the results of 31 studies with a total of 5,069 participants. 1
Studies had an average sample size of 164 (ranging from 20 16 to 911 29 ). Fifteen of the 2 studies included participants with breast cancer 11, 13-17, 20, 22, 25, 26, 28, 30, 32, 35, 36 . Other cancers 3 studied included ovarian 23 and mixed cancer types 10, 12, 18, 19, 21, 23, 24, 29, 31, 33, 34, [37] [38] [39] . One 4 study did not specify the types of cancer that participants were diagnosed with 27 . The most 5 commonly studied side effect was post-treatment nausea (77% [10] [11] [12] 14 39 ). The remaining studies included participants undergoing surgery [14] [15] [16] and radiotherapy 18, 21 . Twenty-six of the studies measured anticipation of side effects prior to the first treatment, 1 two studies measured anticipation prior to each of multiple cycles of treatment (one of which 2 also measured anticipation prior to the first treatment), and the final three studies measured 3 anticipation prior to any treatment session but not the first. Experience of the side effect was 4 measured after the first treatment in 13 of the studies, after each of multiple treatment 5 sessions in 13 of the studies, and any treatment other than the first in five studies. 6
Association between anticipation and experience of side effects 7
Analyses were conducted to investigate the overall effect of anticipation on each of 8 the seven side effects: anticipatory nausea, post-treatment nausea, post-treatment vomiting, 9 fatigue, pain, skin reactions, and problems with concentration (Table 1) . Analyses were also 10 conducted to investigate differences in effect sizes for each side effect in patients with and 11 without previous treatment experience (Table 2 ). An insufficient number of studies meant 12 that analyses could not be conducted for anticipatory nausea in patients with no prior 13 treatment experience and for pain, problems with concentration, and skin reactions in patients 14 with some previous treatment experience. 
Differences in effect in patients with and without prior treatment experience 7
Contrary to the main hypothesis, no significant differences in effect sizes were found 8 in patients with and without prior treatment experience for post-treatment nausea, post-9 treatment vomiting, fatigue, pain, problems with concentration, and skin reactions (Table 4) . 10
The difference between effect sizes for the relationship between anticipation of side effects 11 and the experience of anticipatory nausea in patients with and without prior treatment or no prior experience of treatment separately. When studies that measured side effects in 22 patients with and without previous treatment exposure were analysed together (See Table 1),  23 the largest effect sizes were reported for anticipatory nausea and problems withconcentration, although the conclusiveness of the latter is mitigated by the fact that only two 1 studies were included. Nonetheless, future research in the area of anticipated cognitive 2 impairment following cancer treatment is required, particularly given the rising report of this 3 form of potential impact from treatment in both the scientific (e.g., Janelsins et al. 49 ) and 4 non-scientific media (e.g., the New York Times 50 ) including non-government cancer support 5 organizations around the world (e.g., MacMillan in the UK 51 , the Breast Cancer Network in 6 Australia 52 , and the Fred Hutchinson Center in the US 53 ). 7
It is also interesting to note that although all side effects were positively associated 8 with anticipation, post-treatment vomiting had the smallest effect size. Subsequent analysis 9 separated studies where side effects were measured in patients who had not been previously 10 exposed to treatment (see Table 2 ), from those where patients had previous treatment 11 exposure (see Table 3 ). In the first case, the mechanism is hypothesised to involve response 12 expectancies based upon information obtained directly or indirectly from expert or lay 13 sources, whereas for the second conditioning could be at least part of the explanation. In both 14 of these, post-treatment nausea remained the smallest effect, and was actually reduced to non-15 significance in patients with no prior treatment experience after adjusting for publication bias. 16 This result could reflect real or anticipated effects of any anti-emetics provided, an issue 17 future research might address. 18 We undertook a direct comparison between studies reporting data after a single 19 treatment exposure (where the opportunity for classical conditioning of response was 20 eliminated) with studies where side effect experience was measured after the patient had 21 received multiple treatment cycles (where effects were likely a combination of expectations 22 raised before treatment (i.e., cognitive expectancies) and reactions learned though experience 23 The implications of the findings for clinical practice should be considered. Several 14 studies included in this review recommended providing patients with information prior to 15 treatment in order to alter patient expectations. Although intervention studies provided some 16 support for the use of acupressure bands for reducing nausea 21 and hypnosis for reducing 17 post-surgery pain and distress 16 , manipulations of the information given to patients did not 18 result in changes in side-effects 16 . Shelke et al. 19 found that providing information about the 19 effectiveness of an antiemetic successfully altered patient expectations. However, pre-20 intervention anticipation and not post-intervention anticipation was predictive of subsequent 21 side effects. This suggests that simply changing patient education regarding side effects may 22 not be effective in reducing expectancy effects. 23 The data presented here are subject to significant limitations. The most significant of 24 these is the inability to account for variance arising from an array of variables likely to impactboth the predictor variable, anticipated effect of treatment, and the outcome variable, report 1 of side effects. For example, it is possible that variables like education, IQ, depression, 2 anxiety, locus of control and optimism would all impact ratings of anticipation and the side 3 effects experienced, and the extent to which these are positive or negative, irrespective of 4 messages received about likely effects or any conditioning experienced. There is some 5 support for this from an experimental study of pain expectancies, which found that pain 6 expectancies played a mediating role between catastrophizing and depression and the actual 7 pain experienced 54 , although further research is required to test this. Furthermore, the nature 8 and intensity of the chemotherapy regime and the medication provided to alleviate side 9 effects are all potential confounds of reported side effects. There may also be a 10 differentiated impact of the type of treatment on the side effects that patients 11 experience. This was not examined in the present study due to the small number of 12 studies that included participants undergoing treatment other than chemotherapy. 13
More research is needed to examine the relationships between anticipation of side 14 effects and actual experience of side effects in patients undergoing radiotherapy and 15 surgery before meta-analysis can be conducted to provide meaningful insight. 16 Our results confirm existing findings; anticipation of side effects positively predict the 17 experience of these. In addition, our findings extend those of others by demonstrating their 18 impact in a reasonably recent area of research in side effects of cancer treatment; cognition. 19 Importantly, they highlight the potentially "additive" effects of conditioning following 20 treatment on the impact made from expectations generated before any treatment, but only for 21 anticipatory nausea. The failure to find an additive influence from treatment experience for 22 other side effects suggests an important role for cognition in predicting treatment experience. 23
Future research could usefully explore patient reports of messages received about 1 likely treatment effects both before and during treatment, and from whom these messages 2
originate. 3
In terms of conditioned responses, interview data could identify cues (i.e., the 4 conditioned stimulus) that precede anticipatory nausea and vomiting in an attempt to develop 5 strategies that could mitigate these associations. Further exploration of the anticipated 6 outcomes attached to preventive therapies for side effects might also usefully identify 7 strategies for minimisation of adverse treatment events. An increasing focus on the 8 importance of measuring patient reported outcomes in cancer patients and survivors bodes 9 well for increased concern about patient reported side effects and improved commitment 10 from health providers to assist in their mitigation. Note: *p < 0.05, **p < 0.01, ***p < 0.001, a Only one study examined expectancies and experience of anticipatory nausea prior to any treatment, therefore there were not enough data to run the meta-analysis. b Egger's test confirmed a publication bias, therefore adjusted effect size calculated using Duval and Tweedie's trim-and-fill method. c Only two studies examined the relationship between response expectancies and problems with concentration, therefore publication bias analysis could not be conducted. Results should be interpreted with caution. Problems with concentration 
